RPG Life Sciences Ltd

RPG Life Sciences Ltd

₹ 2,640 -0.15%
11 Aug 4:01 p.m.
About

Incorporated in 2007, RPG Life Sciences Ltd manufactures and markets Formulations (Finished Dosage Forms) and Active Pharma Ingredients[1]

Key Points

Business Overview:[1]
RPGLS is a part of the RPG Group. It started as a joint venture with G.D Searle and was renamed when G.D Searle withdrew its India operations. Currently, the group has major listed companies like KEC International, CEAT, Zensar Tech, etc.
RPGLS is an integrated research based pharmaceutical company operating in domestic and international markets in branded formulations, global generics and APIs

  • Market Cap 4,366 Cr.
  • Current Price 2,640
  • High / Low 3,082 / 1,731
  • Stock P/E 37.4
  • Book Value 366
  • Dividend Yield 0.92 %
  • ROCE 25.7 %
  • ROE 19.3 %
  • Face Value 8.00

Pros

  • Company is almost debt free.

Cons

  • Stock is trading at 7.21 times its book value

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
173 143 169 182 180 177 196
124 118 133 143 140 144 152
Operating Profit 49 25 35 39 40 33 43
OPM % 28% 18% 21% 21% 22% 19% 22%
3 115 5 16 -5 14 5
Interest 0 0 0 0 0 0 1
Depreciation 5 5 5 5 5 6 6
Profit before tax 47 135 35 49 29 40 41
Tax % 26% 13% 26% 25% 24% 26% 26%
35 117 26 37 22 30 31
EPS in Rs 21.12 70.95 15.90 22.28 13.38 18.08 18.60
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2025 Mar 2026 TTM
653 708 734
493 560 579
Operating Profit 161 148 155
OPM % 25% 21% 21%
95 29 29
Interest 2 2 1
Depreciation 21 21 22
Profit before tax 233 154 160
Tax % 21% 25%
183 115 120
EPS in Rs 110.79 69.64 72.34
Dividend Payout % 22% 34%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: %
TTM: 8%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: -5%
Stock Price CAGR
10 Years: 20%
5 Years: 37%
3 Years: 31%
1 Year: 15%
Return on Equity
10 Years: %
5 Years: %
3 Years: %
Last Year: 19%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2025 Mar 2026
Equity Capital 13 13
Reserves 517 592
0 20
127 168
Total Liabilities 658 793
172 197
CWIP 16 23
Investments 127 85
343 488
Total Assets 658 793

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2025 Mar 2026
78 56
-42 86
-27 -21
Net Cash Flow 9 122
Free Cash Flow 151 -9
CFO/OP 81% 63%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2025 Mar 2026
Debtor Days 48 60
Inventory Days 159 179
Days Payable 135 141
Cash Conversion Cycle 72 99
Working Capital Days 45 64
ROCE % 26%

Insights

In beta
Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
API Revenue Share
% of total revenue

Log in to view insights

Please log in to see hidden values.

Login
Domestic Formulations Revenue Share
% of total revenue
International Formulations Revenue Share
% of total revenue
Sales Force Productivity (PCPM - Overall)
INR Lakhs per rep per month
New Product Contribution (DF sales from launches since FY19)
% of DF sales
DF Growth vs IPM Market Growth
% YoY growth
Doctors Enrolled on RPG Serv Platform
Number of doctors
Specialty Sales Force Productivity (PCPM)
INR Lakhs per rep per month
R&D Expenditure (Percentage of Turnover)
% ・Standalone data

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
72.82% 72.82% 72.82% 72.82% 72.82% 72.95% 72.95% 72.95% 72.95% 72.95% 72.95% 72.95%
0.46% 0.56% 0.90% 1.15% 1.35% 1.30% 1.46% 1.35% 1.11% 1.00% 0.87% 0.95%
1.57% 1.77% 2.16% 2.61% 5.45% 6.06% 6.14% 6.49% 6.70% 7.04% 7.45% 8.68%
25.15% 24.85% 24.12% 23.44% 20.40% 19.70% 19.46% 19.22% 19.23% 19.01% 18.72% 17.42%
No. of Shareholders 21,08821,86622,13722,23223,48124,89124,86725,83226,65725,90525,28223,886

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Concalls